医学院


 
导师代码: 20107
导师姓名: 钟磊
性    别:
特    称:
职    称: 副教授
学    位: 理学博士学位
属    性: 专职
电子邮件: zhl7235301@163.com

学术经历:   2009.09-2012.06,四川大学,华西药学院,药剂学,硕士; 2012.09-2015.06,四川大学,生物治疗国家重点实验室,化学生物学,博士; 2015.07-2019.03,电子科技大学附属医院·四川省人民医院,助理研究员; 2015.10-2019.03,四川大学,生物治疗国家重点实验室,博士后(在职); 2017.01-2021.12,电子科技大学医学院,讲师; 2019.04至今,电子科技大学附属医院·四川省人民医院,副研究员; 2022.01至今,电子科技大学医学院,副教授; 2022.05-2023.06,瑞典乌普萨拉大学,访问学者。

个人简介:   钟磊,博士,副教授/副研究员,硕士生导师,四川省省级人才计划入选者,四川省卫健委第十四批学术技术带头人后备人选,第二届中国药理学会治疗药物监测研究专委会青年委员会委员,四川省抗癌协会肿瘤临床药学专委会常务委员,四川省药理学学会治疗药物监测研究专委会常务委员,四川省药理学学会理事会理事。2012年6月毕业于四川大学华西药学院药剂学专业,获理学硕士学位;2015年6月毕业于四川大学生物治疗国家重点实验室化学生物学专业,获理学博士学位;2015年7月入职电子科技大学附属医院·四川省人民医院,主要从事抗肿瘤靶向药物研发和肿瘤耐药机制的研究工作。

科研项目:   近年来主持包括国家自然科学基金项目、中国博士后面上项目、四川省科技厅项目、四川省卫健卫课题、成都市科技局项目、中央高校基金,以及吴阶平基金等在内的各级科研项目10余项。

研究成果:   发表学术论文50余篇,其中,以一作或通讯作者身份发表SCI论文近30篇,IF>5分16篇,最高影响因子40.8,他引1000余次;申请发明专利4项,现已授权3项;作为项目完成人获四川省医学科技一等奖和二等奖各1项。代表性论文如下: 1. Ma Tingnan, et al. SETDB1: Progress and prospects in cancer treatment potential and inhibitor research. Bioorg Chem, 2024, 145: 107219. (通讯作者) 2. Hou Yingying, et al. Insights into vaccines for elderly individuals: from the impacts of immunosenescence to delivery strategies. NPJ Vaccines, 2024, 9 (1): 77. (并列通讯) 3. Zhong Lei, et al. Genetic differences between primary and metastatic cancer: a pan-cancer whole-genome comparison study. Signal Transduct Target Ther, 2023, 8 (1): 363. 4. Peng Haoyuan, et al. Ganoderma lucidum: Current advancements of characteristic components and experimental progress in anti-liver fibrosis. Front Pharmacol, 2023, 13: 1094405. (并列一作) 5. Lu X, Zhong L, et al. Identification of ATF3 as a novel protective signature of quiescent colorectal tumor cells. Cell Death Dis, 2023, 14 (10): 676. (并列一作) 6. Jiang Die, et al. Research progress of VEGFR small molecule inhibitors in ocular neovascular diseases. Eur J Med Chem, 2023, 257: 115535. (并列一作) 7. Peng XR, et al. Emetine, a small molecule natural product, displays potent anti-gastric cancer activity via regulation of multiple signaling pathways. Cancer Chemother Pharmacol, 2023, 91 (4): 303-315. (通讯作者) 8. Zhao ZP, et al. Role of histone methyltransferase SETDB1 in regulation of tumourigenesis and immune response. Front Pharmacol, 2022, 13: 1073713. (通讯作者) 9. Zhong Lei, et al. Recent advances in small-molecular therapeutics for COVID-19. Precision Clinical Medicine, 2022, 5: pbac024. 10. Peng XR, et al. Targeting Indoleamine Dioxygenase and Tryptophan Dioxygenase in Cancer Immunotherapy: Clinical Progress and Challenges. Drug Des Devel Ther, 2022, 16: 2639-2657. (通讯作者) 11. Zhong Lei, et al. Small Molecules in Targeted Cancer Therapy: Advances, Challenges, and Future Perspectives. Signal Transduction and Targeted Therapy, 2021, 6: 201. 12. Yang ZY, et al. Discovery of BAZ1A bromodomain inhibitors with the aid of virtual screening and activity evaluation. Bioorg Med Chem Lett, 2021,33: 127745. (通讯作者) 13. Peng XR et al. Targeting H3K36 methyltransferases NSDs: a promising strategy for tumor targeted therapy, Signal Transduction and Targeted Therapy, 2021, 6 (1): 0-220. (通讯作者) 14. Su Lingyu, et al. Anti-oral squamous cell carcinoma effects of a potent TAZ inhibitor AR-42. Journal of Cancer, 2020, 11(2): 364-373. (通讯作者) 15. Peng Qian, et al. Association of elevated Yes-associated protein expression with gastric cancer and its clinicopathological features. J Biosci Med, 2020, 8, 96-109. (通讯作者) 16. Zhong Lei, et al. Preclinical assessment of histone deacetylase inhibitor quisinostat as a therapeutic agent against esophageal squamous cell carcinoma. Investigational New Drugs, 2019, 37: 616-624. 17. Zhou Yanping, et al. Design, synthesis and in vitro tumor cytotoxicity evaluation of 3,5-diamino-N-substituted benzamide derivatives as novel GSK-3β small molecule inhibitors. Chem. Biodiversity, 2019, 16: e1900304. (通讯作者) 18. Zhong Lei, et al. Protective effect of ethyl vanillin against Aβ induced neurotoxicity in PC12 cells via the reduction of oxidative stress and apoptosis Experimental and Therapeutic Medicine, 2019, 17: 2666-2674. 19. Zhong Lei, et al. Relevance of methylenetetrahydrofolate reductase gene variants C677T and A1298C with response to fluoropyrimidinebased chemotherapy in colorectal cancer: a systematic review and meta-analysis. Oncotarget, 2018, 9 (58): 31291-31301. 20. Yang Ling-Ling, et al. X-ray crystal structure guided discovery of new selective, substratemimicking sirtuin 2 inhibitors that exhibit activities against non-small cell lung cancer cells. European Journal of Medicinal Chemistry, 2018, 155: 806-823. (并列一作) 21. Zhong Lei, et al. Relevance of MTHFR polymorphisms with response to floropyrimidine based chemotherapy in oesophagogastric cancer: a meta-analysis. BMJ Open, 2018, 8: e020767. 22. Zhong Lei, et al. Preclinical pharmacodynamic evaluation of drug candidate SKLB-178 in the treatment of non-small cell lung cancer. Oncotarget, 2017, 8 (8): 12843-12854. 23. Zhong Lei, et al. A preclinical evaluation of a novel multikinase inhibitor, SKLB-329, as a therapeutic agent against hepatocellular carcinoma. International Journal of Cancer, 2014, 135 (12): 2972-2983. 24. Zhong Lei, et al. A prediction model of substrates and non-substrates of breast cancer Resistance protein (BCRP) developed by GA–CG –SVM method. Computers in Biology and Medicine, 2011, 41 (11): 1006-1013.

专业研究方向:
专业名称 研究领域/方向 招生类别
105500药学 02药物研究与转化 硕士专业学位


学院列表
01  信息与通信工程学院
02  电子科学与工程学院
03  材料与能源学院
04  机械与电气工程学院
05  光电科学与工程学院
06  自动化工程学院
07  资源与环境学院
08  计算机科学与工程学院(网络空间安全学院)
09  信息与软件工程学院(示范性软件学院)
10  航空航天学院
11  数学科学学院
12  物理学院
13  医学院
14  生命科学与技术学院
15  经济与管理学院
16  公共管理学院
17  外国语学院
18  马克思主义学院
21  基础与前沿研究院
22  通信抗干扰全国重点实验室
23  电子科学技术研究院
28  电子科技大学(深圳)高等研究院
31  集成电路科学与工程学院(示范性微电子学院)
90  智能计算研究院